Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 51.72 | -48.84 | 36.72 | -- | -- |
| EBIT | -381.87 | -314.37 | -128.26 | -21.52 | -65.29 |
| Net Profit | -379.26 | -310.33 | 10.32 | -22.26 | -39.98 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-21 | Dec-20 |
| EBIT-Margin
| -9,181.96 | -9,181.96 | -8,350.08 | -3,788.03 | -14,575.89 |
| Net Margin
| -19,372.40 | -115,859.20 | -2,199.76 | -- | -10,050.90 |
| Return on equity
| -153.05 | -247.68 | -211.23 | -74.36 | -117.28 |
| Return on Capital
| -90.56 | -128.20 | -- | -56.04 | -72.95 |
| Return on Assets
| -70.97 | -98.80 | -94.92 | -49.71 | -60.85 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.29 | 0.35 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
ROE
-211.23
Lower than Peers by 193.63
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-211.23
|
-74.36
|
-117.28
|
-267.52
|
-274.54
|
-504.73
|
|||||
|
Peer Median
|
-17.61
|
--
|
--
|
--
|
--
|
--
|
ROA
-94.92
Lower than Peers by 82.40
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-94.92
|
-49.71
|
-60.85
|
-102.35
|
-131.49
|
-149.62
|
|||||
|
Peer Median
|
-12.52
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-8,350.08
Lower than Peers by 8,292.25
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-8,350.08
|
-3,788.03
|
-14,575.89
|
--
|
--
|
--
|
|||||
|
Peer Median
|
-57.83
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-2,199.76
Lower than Peers by 2,137.41
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
Dec-17
|
Dec-16
|
Dec-15
|
Dec-14
|
Dec-13
|
Dec-12
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Zosano Pharma (ZSAN)
|
-2,199.76
|
-3,812.10
|
-10,050.90
|
-28,693.89
|
-8,906.30
|
-415,785.71
|
|||||
|
Peer Median
|
-62.35
|
--
|
--
|
--
|
--
|
--
|
Cash Profit Margin
-0.01
--
(Net profit + Depreciation) / Gross Sales * 100
Revenue Growth
36.72
Higher than Peers by 13.84
Year on year growth in net sales
EBIT Growth
-128.26
Lower than Peers by 142.46
Year on year growth in operating profit (EBIT)
Net Profit Growth
-123.23
Lower than Peers by 134.41
Year on year growth in profit after tax
Solvency
Debt to Equity
--
--
Total debt / Net worth
Short term debt to equity ratio
0.24
--
(Short term borrowings / Net worth)
Current Ratio
1.61
Lower than Peers by 3.03
Current Assets / Current Liabilities and Provisions
Quick Ratio
1.61
Lower than Peers by 3.00
(Current Assets - Inventory) / Current Liabilities and Provisions
Interest Coverage
-333.50
Lower than Peers by 334.36
Earning before interest and taxes (EBIT) / Interest Expenses
Operating Efficiency
Debtors to sales
16.24
Lower than Peers by 9.38
Debtors outstanding / Net Sales * 100
Asset Turnover
0.01
Lower than Peers by 0.24
Sales / Average Total Assets
Receivable days
--
--
Average Debtors / Sales * 365
Inventory Days
--
--
Average Inventory / Sales * 365
Payable days
--
--
Average Creditors / Cost of goods sold * 365
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
Valuation
Price / Book Value
0.16
Lower than Peers by 3.43
Current share price divided by book value per share in the latest financial year
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
EV/EBITDA
0.10
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
Market Cap
3
Lower than Peers by 71
Current Share price multiplied by latest total number of shares outstanding